Amlow

Quick links to important sections

Amlow

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amlow

What is Amlow? A Foundational Overview

Property Description
Active ingredient Amlodipine (Amlodipine besilate)
Form Oral Solid Preparation (Tablet)
Pharmacological Class Calcium Channel Blocker (Dihydropyridine)
General Purpose Managing elevated circulatory pressure
Origin Synthetic Compound

What is Amlow and its Pharmacological Identity?

Amlow is a proprietary, synthetic cardiovascular medication containing the active chemical substance Amlodipine, typically formulated as Amlodipine besilate. It is classified within the dihydropyridine group of Calcium channel blockers (CCBs). This classification defines the drug's primary function as an agent that regulates the flow of calcium ions into specific muscle cells, a property of this drug class. As a prescription-only medicine, Amlow is positioned for use in adult patients who require chronic daily management of vascular conditions.

Composition, Origin, and Pharmaceutical Form

Its core substance, Amlodipine besilate, is a synthetic chemical compound, meaning it is chemically manufactured rather than naturally derived. This medicine is designed as an oral solid preparation, most commonly a tablet, intended for ingestion. Its formulation as a single-ingredient product means it contains only Amlodipine alongside necessary pharmaceutical excipients. The substance is used as a standard treatment for essential hypertension and angina pectoris, establishing its role in cardiovascular maintenance therapy.

General Purpose: What is the Main Action of this Type of Medication?

This medication's core purpose is to facilitate vascular relaxation by affecting the muscle cells lining the arteries. As a Calcium channel blocker, Amlow reduces the ability of calcium to enter these cells, preventing them from constricting and thereby forcing the blood vessels to relax and widen, a process known as vasodilation. This direct action on the vasculature achieves the general therapeutic goal of reducing the total peripheral resistance within the circulatory system, which consequently lessens the work required by the heart and aids in managing elevated pressure in the circulation.

Regulatory References

  1. Amlodipine: MedlinePlus Drug Information
  2. Norvasc (Amlodipine) - Referral EMA

What side effects are possible with Amlow?

Possible Side Effects and Safety Information

The medicine's safety profile is formally classified by government regulatory authorities based on the frequency and the System-Organ Class (SOC) affected. This classification helps differentiate common, expected reactions from rare, serious adverse events.

Frequency-Classified Adverse Reactions

The most frequently reported adverse reaction is Oedema (swelling), often peripheral, which is officially classified as Very Common. Reactions classified as Common include Headache, Dizziness, Somnolence, Palpitations, Flushing, Nausea, Abdominal pain, Fatigue, and Asthenia.

These common reactions, such as headache and dizziness, are noted in regulatory documents to occur more frequently especially at the beginning of the treatment. Additionally, the incidence of oedema is documented as a dose-related adverse effect.

Serious Adverse Reactions and Safety Constraints

Rare but serious adverse reactions documented in official labeling include the potential for Worsening Angina and Acute Myocardial Infarction, which can develop after starting or increasing the dose, particularly in individuals with pre-existing severe coronary artery disease. Severe skin reactions, such as Erythema Multiforme and Stevens-Johnson Syndrome, are also classified as Very Rare events.

Safety limitations include a Contraindication for patients with known hypersensitivity to the drug or other similar medications (dihydropyridines). Caution is advised for patients with severe aortic stenosis due to the risk of symptomatic hypotension. The drug’s clearance is also noted to be decreased in patients with hepatic impairment, a factor considered in regulatory safety notes for such specific populations.

Overdose and Emergency Response

Overdose and When to Seek Help

Amlow (amlodipine) overdose is defined by government regulatory documents as a severe risk of acute circulatory compromise, requiring immediate professional intervention. The officially documented clinical presentation is centered on marked and prolonged systemic hypotension due to excessive peripheral vasodilation, which may lead to shock and potentially a fatal outcome. Signs can include extreme blood pressure drops, reflex tachycardia or bradycardia, and a decreased level of consciousness, such as somnolence and confusion.

When to Seek Immediate Medical Help

Regulatory authorities explicitly state that any suspicion of overdose requires the patient to seek immediate medical attention or contact emergency services immediately. Management must occur in a hospital setting with continuous cardiac monitoring.

Official Management Procedures

No specific antidote is known to reverse the effects of amlodipine. Management is primarily symptomatic and supportive treatment. Procedures documented in regulatory labeling include placing the patient in a supine position, considering gastric lavage or activated charcoal if ingestion was recent, and administering intravenous fluids and potentially vasopressors to correct hypotension. Intravenous calcium gluconate may also be considered to help counteract the calcium channel blockade effects.

Therapeutic Uses of Amlow

What Amlow Treats: Main Uses and Benefits

Amlow (amlodipine) is commonly used across domains where additional symptomatic support is needed in contexts involving heightened systemic burden. In clinical practice, the medication may assist with managing symptoms related to systemic imbalance and is considered relevant for easing symptoms linked to organ-specific functional stress. Its use helps patients cope more steadily with difficult episodes.

The medication is applied across conditions involving episodic or fluctuating manifestations, often used for managing symptoms related to systemic imbalance, such as those associated with high blood pressure, and symptoms of physical discomfort, as seen with chest discomfort (angina). It is generally applied in clinical settings that involve systemic imbalance, where symptoms create noticeable physiological strain. Its use contributes to maintaining a sense of stability when symptoms are more noticeable.


Supporting Stability in High Blood Pressure (Hypertension)

Amlow is relevant in conditions characterized by periods of heightened symptoms associated with persistently elevated blood pressure readings. The medication provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of increased physiological stress.


Easing Discomfort Associated with Chest Symptoms

This domain addresses symptoms related to physical discomfort, specifically those associated with chest tightness that may appear suddenly or fluctuate. It is relevant for managing symptoms that interfere with daily comfort, and generally supports the patient during episodes of heightened discomfort by easing distress.


Quick Fact: Focus on Physical Discomfort Amlow is commonly used when symptoms create noticeable functional strain related to systemic imbalance or organ-specific functional stress, offering supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Eligibility for Amlow (Amlodipine) Use

Official regulatory documents define specific populations who are permitted to use Amlow and groups for whom use is strictly prohibited or restricted. All eligibility is based solely on documented information in government regulatory labeling.

Contraindicated Populations (Cannot Use) Conditional or Restricted Use
Patients with a known hypersensitivity to Amlodipine or any other dihydropyridine derivatives. Use requires caution in patients with hepatic impairment (liver problems) due to reduced drug clearance.
Patients experiencing severe hypotension (markedly low blood pressure) or shock (including cardiogenic shock). Caution is advised for patients with severe congestive heart failure or severe aortic stenosis.

Age-Group Eligibility Rules

Amlow is approved for use in adult patients (18 years and older). Use in pediatric patients is established for treating hypertension only, specifically for children ages 6 to 17 years. Safety and efficacy for the treatment of children under 6 years of age are not established by regulatory bodies. Older patients may require lower initial doses as drug clearance can be reduced.

Pregnancy and Lactation Status

The medicine is generally not recommended during pregnancy unless the potential benefit justifies the potential risk, as human safety data are limited. For nursing mothers, Amlow is excreted into human milk, and regulatory labeling advises discontinuing nursing while administering the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Amlow (Amlodipine) is extensively metabolized in the liver, primarily through the Cytochrome P450 3A4 (CYP3A4) enzyme pathway. Therefore, interactions are primarily governed by the concurrent use of strong or moderate CYP3A4 inhibitors, which can increase exposure to Amlodipine and potentially increase the risk of its side effects. This group includes certain antifungal medications (like ketoconazole, itraconazole) and select macrolide antibiotics (like clarithromycin).

A significant interaction exists with the cholesterol-lowering medication Simvastatin. Co-administration of Amlodipine can significantly increase Simvastatin plasma concentrations, raising the risk of muscle toxicity (myopathy, rhabdomyolysis). To mitigate this risk, regulatory agencies advise that the Simvastatin dose must be limited to 20 mg daily when used concurrently with Amlodipine.

Other documented interactions include:

  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Long-term use of NSAIDs may reduce the blood pressure-lowering effect of Amlodipine.
  • Grapefruit juice: Consumption may increase the systemic exposure of Amlodipine, and monitoring for blood pressure changes is advised.

Conversely, clinical studies have demonstrated that the co-administration of Amlodipine with other products, such as the heartburn medication Cimetidine, the erectile dysfunction drug Sildenafil, and the statin Atorvastatin, does not result in clinically significant changes in the pharmacokinetic profiles of either drug.

Mechanism of Action

Targeted Inhibition of Arterial Calcium Channels

Amlow acts as a calcium channel inhibitor, binding directly to the L-type calcium channels (L-VGCCs) located on the membranes of peripheral artery smooth muscle cells. This molecular action impedes the influx of calcium ions (Ca^2+) into the cell, which initiates muscle contraction. Amlow exhibits selectivity, targeting vascular channels more prominently than cardiac channels.

Inducing Vascular Smooth Muscle Relaxation

By blocking the calcium influx, Amlow interrupts the molecular cascade that leads to muscle fiber shortening, resulting in vascular smooth muscle relaxation (vasodilation). This widening of the arteries decreases the peripheral vascular resistance, which is the pressure opposing blood flow from the heart.

Modulating Systemic Resistance and Afterload

The resulting widespread arterial vasodilation directly modulates systemic hemodynamics via reduction of total peripheral resistance and cardiac afterload. This physiological change results in a reduction of opposing pressure within the circulatory system and alters blood flow dynamics.

Dosage and Administration Information

How to Use Amlow

Amlow (amlodipine) is administered according to a highly structured daily protocol defined in professional labeling. Its use is characterized by a specific route, precise dose ranges, and a fixed frequency pattern intended for chronic maintenance.


Administration Scope

Instruction Detail
Route of administration Oral (by mouth), utilizing tablet or liquid preparations.
Dosing schedule (Adults) Initial Dose: Typically 5 mg once daily. Maximum Dose: 10 mg once daily.
Timing in relation to meals Can be taken with or without food.
Preparation requirements Liquid forms must be measured precisely and/or shaken well before administration.
Age-group rules Older Adults/Hepatic Impairment: Suggested starting dose is 2.5 mg once daily. Pediatric (6–17 years): Dosing is 2.5 mg to 5 mg once daily.
Missed-dose rules If a whole day is skipped, omit the missed dose and resume the normal schedule; do not double the dose.
Special procedural conditions The dose should be administered at approximately the same time each day. Titration to a higher dose, if needed, should generally proceed over 7 to 14 days.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern Once daily (OD) for long-term use
Use-context constraints Fixed daily frequency; flexible relation to food intake

Resulting Procedural Structure

Connection to the overall use protocol:

The professional instructions establish a standardized long-term daily maintenance regimen rooted in a single oral administration. This protocol dictates precise dose ranges and a defined interval for dose adjustment, ensuring consistent administration according to standardized protocols. The flexibility regarding meal timing is balanced by the strict requirement for once-daily use at a consistent time, which defines the essential pattern of use.

Recent Clinical Evidence

Research evidence: Overview of Studies for Amlow (Amlodipine)


Evidence for Use in Supporting Stability in High Blood Pressure

The research base for Amlow's use in managing elevated blood pressure was evaluated in large-scale Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews. These studies were structured to evaluate Amlow in research contexts involving fluctuating or unstable symptoms associated with high pressure. The main focus of this research was studied for changes in Systolic and Diastolic Blood Pressure (BP) from the start of the study. The research also explored long-term outcomes related to major health events, such as cardiovascular events, over periods sometimes spanning two to five years.

The findings describe patterns observed in the studies across diverse adult populations. Regulatory evaluation is often applied to research involving this area. However, research describes that while short-term changes in blood pressure were a key focus in research, the evidence often comes from trials where Amlow was evaluated in use as part of a combination regimen, meaning specific contributions require careful analysis.


Evidence for Easing Discomfort Associated with Chest Symptoms

Amlow was studied for its application in managing symptoms related to physical discomfort, specifically chronic stable and vasospastic chest discomfort (angina). Placebo-controlled trials explored short-term symptom patterns and changes. These studies was studied for outcomes related to physical discomfort and physiological strain, tracking the frequency of discomfort episodes.

The research in this domain is broadly recognized as high-level evidence. However, research exploring short-term symptom changes is primarily focused on chronic, prophylactic use, and limited information exists on its effect when symptoms become more noticeable or during an acute or sudden episode of physical discomfort.


What is Still Uncertain About Amlow

While extensive high-level research exists for the core indications, regulatory reviews point to several areas where the evidence is limited or uncertain. Data are still insufficient for long-term outcomes in children and adolescents, as current data are still restricted to short-term physiological responses. Furthermore, the use of Amlow during acute or disruptive episodes has not been widely studied.

Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly. In some specific high-risk subgroups and those with complex comorbidities, data for certain groups remain insufficient, and subgroup findings are uncertain.

Key Studies & References

  1. Drug Class Review on Calcium Channel Blockers (DERP/OHSU)

Frequently Asked Questions (FAQ)

Common questions about Amlow (FAQ)


Q: How quickly can I expect Amlow to start working?

Official drug information describes the onset of action as gradual. The maximum concentration of the drug in the blood is typically reached 6 to 12 hours after taking it. For this reason, the prescribing healthcare provider may assess the full effect and consider dose adjustments, if needed, over a period of 7 to 14 days.


Q: Does Amlow work right away or does it build up over time?

Regulatory documents indicate that the effect of Amlow is gradual and supports a smooth, sustained reduction in blood pressure over time. The medicine is intended for chronic, daily use. The suggested titration period before a dose increase is often 7 to 14 days, allowing the full therapeutic effects to be established.


Q: Do the side effects of Amlow go away after a few weeks?

The official safety profile notes that common side effects, such as headache, dizziness, and sleepiness (somnolence), occur more frequently especially when starting the treatment. While this suggests they may lessen, the official product information does not specify an exact timeframe for how long these reactions typically last.


Q: Can Amlow cause a cough like some other heart medicines?

Cough is listed in the official adverse reactions table as a possible effect. This means it is documented in the regulatory safety profile with an uncommon frequency classification.


Q: Are there any long-term side effects associated with Amlow use?

The official safety profile includes reporting of adverse reactions that have been observed during long-term use. These may include both common reactions and very rare but serious reactions, such as severe skin reactions like Erythema Multiforme, which are documented in the official labeling.


Q: Is Amlow considered a safe medication for long-term use?

Amlow is indicated for chronic, long-term conditions such as hypertension and angina. Regulatory documents outline the drug’s use in a long-term daily maintenance regimen, and its clinical data support this pattern of chronic use.


Q: What kind of research supports the use of Amlow?

The efficacy and safety of Amlow are supported by evidence found in large-scale studies, including Randomized Controlled Trials (RCTs). These studies, described in official labeling, have focused on outcomes such as blood pressure reduction and overall cardiovascular health.


Q: Is Amlow used for anything other than high blood pressure or chest pain?

Official indications for the active ingredient in Amlow (amlodipine) are limited to the management of hypertension (high blood pressure) and angina pectoris, which includes both chronic stable angina and vasospastic angina. Regulatory labels only approve use for these specific conditions.


Q: Is Amlow available as a generic medicine?

Yes. The active ingredient in Amlow is amlodipine. Regulatory bodies often approve generic formulations of amlodipine for public use, making it widely available in a non-proprietary form.


Q: What is the typical timeframe before a doctor decides Amlow is working?

Official administration protocols state that any dose adjustment should generally be done over a period of 7 to 14 days. This timeframe is suggested for the medicine to reach consistent concentrations in the body, allowing for full effect assessment.


Q: Does the medicine label for Amlow mention any warnings about driving or operating machinery?

The official safety documentation advises caution regarding driving or operating machinery. This is because the ability to perform these tasks may be impaired if side effects like dizziness, headache, fatigue, or nausea occur, particularly when treatment is first started.


Q: What happens when Amlow is stopped?

Regulatory information indicates that abrupt discontinuation of the drug is generally not associated with rebound hypertension (a sudden, significant increase in pressure). Blood pressure is expected to gradually return toward pre-treatment levels.


Q: Does Amlow treat the cause of the condition or just the symptoms?

The regulatory mechanism of action describes that Amlow works by relaxing blood vessels to reduce blood pressure and ease chest discomfort. It acts to manage the symptoms and resulting effects of the conditions; it is not described in official sources as a cure.


Q: What are the benefits of taking Amlow daily?

Clinical studies described in official labeling show that chronic daily administration can lead to the sustained reduction of blood pressure over a 24-hour period. In studies of patients with chest symptoms, chronic daily use was evaluated for the reduction in the incidence of discomfort episodes.


Q: Is Amlow an ACE inhibitor or a beta-blocker?

Official classification states that Amlow belongs to the pharmacological class known as a Calcium Channel Blocker (Dihydropyridine type). It is classified differently from both ACE inhibitors and beta-blockers.


Q: Can I drink alcohol while taking Amlow?

Regulatory guidance notes that consuming alcohol may enhance the blood pressure-lowering effect of the medication. This combination may increase the risk of side effects such as dizziness or lightheadedness. Official guidance notes that due to this potential, concurrent use of alcohol requires caution.


Q: Does Amlow interact with common pain relievers like ibuprofen?

Yes, official documentation states that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a class that includes ibuprofen, may reduce the intended blood pressure-lowering effect of Amlow when used over a long period.


Q: Why is Amlow sometimes combined with other blood pressure drugs?

Amlow is described in regulatory documents for use either alone (monotherapy) or in combination with other anti-hypertensive agents. It is commonly combined with medicines like thiazide diuretics or ACE inhibitors when achieving blood pressure management goals requires more than a single medication.


Q: Why might Amlow be stopped suddenly?

The medication may be stopped by a prescribing healthcare provider if a patient experiences a serious adverse event documented in the official labeling. Examples include a severe allergic reaction, or in rare cases, the worsening of chest symptoms when starting or increasing the dose.


Q: Does Amlow have any impact on heart rate?

Clinical data in official documents indicate that the chronic oral administration of the medicine is generally not associated with a significant change in heart rate. However, one of the common side effects that can be experienced is palpitations, which are a sensation of a rapid or irregular heartbeat.


Q: Is it true that Amlow can cause changes in mood?

Yes, official safety documents list both mood changes, including anxiety, and depression as uncommon adverse reactions in the psychiatric disorders category. This information is based on reporting in clinical settings.


Q: Do official documents mention any effects of Amlow on sexual function?

Yes. Official safety documents list impotence (inability to achieve or maintain an erection) as an uncommon adverse reaction in the reproductive system disorders category. This information is documented in the product's safety profile.


Q: Can Amlow be cut in half if it's too hard to swallow?

Regulatory documents state that Amlodipine tablets may have scoring to allow them to be divided into equal doses, depending on the specific product formulation. However, the exact tablet form and any advice on splitting must be confirmed based on the specific product label provided by the manufacturer.


Q: Is Amlow known to cause allergic reactions?

Yes. Amlow is formally contraindicated in patients with a known hypersensitivity to the drug itself or other similar medicines. Regulatory documents also list allergic reactions as a potential adverse event under the Immune system disorders category.


Q: Why do some people take Amlow in the morning and others in the evening?

Regulatory advice states that the drug should be taken at approximately the same time each day. Because Amlow has a long duration of action (over 24 hours), the specific time, whether morning or evening, is often chosen based on the patient's daily routine to ensure consistent administration.

How should Amlow be stored and disposed of?

How to Store and Dispose of Amlow?

Amlodipine (Amlow) must be stored under specific conditions to maintain its stability, as documented in official regulatory labeling.

Storage Requirements

The tablets must be kept at controlled room temperature, generally between 20 C to 25 C. It is mandatory to protect the medication from light and moisture, and it must not be frozen or refrigerated. The tablets should remain in their original container, which must be kept tightly closed.

Child Safety and Disposal

All medication must be stored securely out of the sight and reach of children.

For disposal, unused or expired Amlow should be returned through a drug take-back program when available. If not, the medicine may be mixed with an unappealing substance, sealed in a bag, and placed in the household trash according to official guidance, ensuring the pills are not crushed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amlow found in:

A-Z Index: